High-performance liquid chromatographic method for the determination of moclobemide and its two major metabolites in human plasma.

[1]  M. Chetty,et al.  Psychotropic Drug Interactions With Valproate , 2005, Clinical neuropharmacology.

[2]  A. Ahmadiani,et al.  Determination of moclobemide in human plasma by high-performance liquid chromatography with spectrophotometric detection. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[3]  I. Whyte,et al.  Moclobemide poisoning: toxicokinetics and occurrence of serotonin toxicity. , 2003, British journal of clinical pharmacology.

[4]  U. Bonnet.  Moclobemide: therapeutic use and clinical studies. , 2003, CNS drug reviews.

[5]  R. Skibiński,et al.  LC determination of moclobemide and three metabolites in plasma. , 2002, Journal of pharmaceutical and biomedical analysis.

[6]  A. Falcão,et al.  Linear regression for calibration lines revisited: weighting schemes for bioanalytical methods. , 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[7]  G. Shenfield,et al.  High-performance liquid chromatography-electrospray ionization mass spectrometry method for the measurement of moclobemide and two metabolites in plasma. , 2001, Journal of chromatography. B, Biomedical sciences and applications.

[8]  D. Yim,et al.  Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19 , 2001, Clinical pharmacology and therapeutics.

[9]  C. Huck,et al.  Recent developments in polymer-based sorbents for solid-phase extraction. , 2000, Journal of chromatography. A.

[10]  N. Wood,et al.  Clinical pharmacology of moclobemide during chronic administration of high doses to healthy subjects , 1998, Psychopharmacology.

[11]  M. S. Mills,et al.  Solid-Phase Extraction: Principles and Practice , 1998 .

[12]  Y. Gaillard,et al.  Moclobemide fatalities: report of two cases and analytical determinations by GC-MS and HPLC-PDA after solid-phase extraction. , 1997, Forensic science international.

[13]  T. Guentert,et al.  Clinical Pharmacokinetics of the Monoamine Oxidase-A Inhibitor Moclobemide , 1995, Clinical pharmacokinetics.

[14]  L. Balant,et al.  Potential of Concentration Monitoring Data for a Short Half‐Life Drug: Analysis of Pharmacokinetic Variability for Moclobemide , 1995, Therapeutic drug monitoring.

[15]  E. Griesser,et al.  Biotransformation of moclobemide in humans , 1990, Acta psychiatrica Scandinavica. Supplementum.

[16]  G. Tucker,et al.  Pharmacokinetics of moclobemide after single and multiple oral dosing with 150 milligrams 3 times daily for 15 days , 1990, Acta psychiatrica Scandinavica. Supplementum.

[17]  A. Korn,et al.  Disposition kinetics of moclobemide, a monoamine oxidase‐A enzyme inhibitor: Single and multiple dosing in normal subjects , 1987, Clinical pharmacology and therapeutics.

[18]  H. Eggers,et al.  Determination of the new monoamine oxidase inhibitor moclobemide and three of its metabolites in biological fluids by high-performance liquid chromatography. , 1987, Journal of chromatography.

[19]  Trevor R. Norman,et al.  Measurement of moclobamide, a new monoamine oxidase inhibitor, by gas chromatography with nitrogen-selective detection. , 1983, Journal of chromatography.